Mirabella Financial Services LLP Takes $2.54 Million Position in argenx SE (NASDAQ:ARGX)

Mirabella Financial Services LLP bought a new position in shares of argenx SE (NASDAQ:ARGX) in the 4th quarter, Holdings Channel reports. The fund bought 4,131 shares of the company’s stock, valued at approximately $2,539,000.

A number of other institutional investors and hedge funds have also bought and sold shares of ARGX. GeoWealth Management LLC boosted its holdings in shares of argenx by 56.3% during the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company’s stock worth $31,000 after acquiring an additional 18 shares during the period. Whipplewood Advisors LLC acquired a new stake in argenx during the 4th quarter worth approximately $37,000. Global Retirement Partners LLC boosted its stake in argenx by 369.2% in the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock valued at $38,000 after purchasing an additional 48 shares during the period. FIL Ltd acquired a new position in argenx in the 4th quarter valued at $38,000. Finally, Jones Financial Companies Lllp increased its position in argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock worth $41,000 after buying an additional 61 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenx Price Performance

Shares of argenx stock opened at $596.20 on Friday. The company’s 50 day moving average price is $602.53 and its two-hundred day moving average price is $605.93. The firm has a market capitalization of $36.23 billion, a P/E ratio of -677.50 and a beta of 0.60. argenx SE has a fifty-two week low of $352.77 and a fifty-two week high of $678.21.

argenx (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.98 by $0.60. The business had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. On average, analysts expect that argenx SE will post 3.13 earnings per share for the current year.

Wall Street Analyst Weigh In

ARGX has been the topic of several research reports. Robert W. Baird upped their price target on shares of argenx from $650.00 to $680.00 and gave the company a “neutral” rating in a research note on Tuesday, March 4th. Sanford C. Bernstein raised shares of argenx from a “market perform” rating to an “outperform” rating in a report on Monday, March 17th. Guggenheim boosted their price target on argenx from $775.00 to $1,100.00 and gave the company a “buy” rating in a research note on Monday, March 10th. Deutsche Bank Aktiengesellschaft upgraded argenx from a “sell” rating to a “hold” rating in a research note on Wednesday, March 12th. Finally, Wells Fargo & Company increased their target price on argenx from $723.00 to $741.00 and gave the stock an “overweight” rating in a report on Friday, February 28th. Three research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $699.28.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.